methylphenidate tablet / Generic mfg. - LARVOL DELTA

Acute administration of methylphenidate modulates functional connectivity during the processing of irrelevant stimuli in Parkinson’s disease patients (MDS Congress 2026) - No abstract available

Clinical • CNS Disorders • Movement Disorders • Parkinson's Disease

The Therapeutic Effect of Methylphenidate Hydrochloride in Conjunction with Sensory Integration Training in Children with Attention Deficit Hyperactivity Disorder. (PubMed, Psychiatry Clin Psychopharmacol) - "Following the treatment, the observation group exhibited notably superior scores in the sensory integration and praxis test, IVA-CPT, and behavior rating scale, with a notably reduced occurrence of complications, in comparison to the control group (P < .05). To summarize, the utilization of methylphenidate hydrochloride alongside sensory integration training has demonstrated promising effectiveness in treating children diagnosed with ADHD and deserves broader implementation."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Late Breaking Abstract - Pulmonary Arterial Hypertension in patients exposed to methylphenidate (ERS 2026) - "PAH may occur in patients treated with MPH. These observations warrant close monitoring."

Clinical • Late-breaking abstract • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Cardiovascular • CNS Disorders • Hepatology • Narcolepsy • Pulmonary Arterial Hypertension • Respiratory Diseases • Sleep Disorder

Is methylphenidate truly cardiac-safe? Insight from biventricular speckle tracking echocardiography in pediatric patients with attention deficit hyperactivity disorder. (PubMed, Eur J Pediatr) - " Subclinical cardiac systolic and diastolic alterations were detected in pediatric ADHD patients treated with methylphenidate. The safety of the drug for the heart is warranted; therefore, careful patient selection, baseline cardiovascular assessment, and follow-up of these patients are strongly recommended."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Cardiovascular • CNS Disorders • Pediatrics • Psychiatry

Chronic psychostimulant exposure and vulnerability to Parkinson's disease: is there a role for brain iron? (PubMed, Neurodegener Dis Manag) - "Recent evidence suggests a potential link between ADHD and an increased risk of PD onset, with psychostimulant exposure--particularly methylphenidate (MPH)--as a possible contributing factor...Finally, we review preliminary neuroimaging evidence of increased nigrostriatal iron content in predominantly MPH-medicated children with ADHD compared with medication-naïve children and neurotypical controls, and we propose recommendations to further evaluate this putative relationship. Importantly, evidence is preliminary, and the proposed hypothetical model should not be used to guide clinical practice currently."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

Regulatory reform and adult methylphenidate dispensing in France: a nationwide interrupted time-series study. (PubMed, BMJ Ment Health) - "Regulatory changes expanding ADHD treatment access may produce rapid prescribing increases, requiring adequate specialist capacity and stimulant use monitoring."

Journal • Retrospective data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Behavior Disorders • CNS Disorders • Mental Retardation • Psychiatry

Deletion of N-ethylmaleimide-sensitive factor in dopamine D2 receptor-expressing cells impairs striatal development and dopaminergic function and induces ADHD-like behaviors in mice. (PubMed, Neuropsychopharmacology) - "Combined administration of methylphenidate and a D2R agonist, quinpirole, alleviated both behaviors, suggesting a potential complementary approach for ADHD treatment. These findings highlight the critical role of NSF in maintaining D2R-associated striatal neuronal populations and suggest that disruption of the NSF-D2R interaction may contribute to ADHD-like phenotypes. This study supports the translational relevance of the Nsf f/f;D2R-Cre model for ADHD and indicates that targeting D2R dysfunction, particularly in treatment-resistant ADHD, may be a promising therapeutic strategy."

Journal • Preclinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Mental Retardation • Psychiatry • DRD2

Association between congenital ptosis and ADHD: a national, cross-sectional study. (PubMed, Br J Ophthalmol) - "This national cross-sectional study is the first to investigate the association between congenital ptosis and ADHD, revealing that nearly 20% of patients with congenital ptosis developed ADHD significantly exceeding that of the general paediatric population. Based on these findings, clinicians should consider early ADHD screening in children with congenital ptosis, especially in those presenting with risk factors allowing for timely intervention and appropriate treatment."

Journal • Observational data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Ophthalmology • Pediatrics • Psychiatry

Cannabinoid type 1 receptor availability imaging in attention-deficit/hyperactivity disorder using [18F]MK-9470 positron emission tomography: study protocol of the CB1-ADHD study. (PubMed, EJNMMI Rep) - "This first investigation of the endocannabinoid system in ADHD will provide crucial insights into disease mechanisms and identify potential therapeutic targets. Results may inform development of novel cannabinoid-based treatments and improve evidence-based therapeutic strategies for ADHD management."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Developmental Disorders • Psychiatry

Spatial inequalities and contextual correlates of methylphenidate dispensing in Jiangsu Province, China. (PubMed, Front Pharmacol) - "Within the annual Lasso models, predictive importance was allocated mainly to economic-demographic indicators in 2019-2020 and more strongly to education-related indicators in 2021-2023. The findings support geographically differentiated monitoring of medication access, dispensing patterns, and prescribing quality."

Journal

Electroencephalographic Signatures of Methylphenidate in ADHD: A Systematic Review and 10 Recommendations for Future Research. (PubMed, J Atten Disord) - "Methylphenidate reliably increased P3 amplitude across tasks, suggesting an improvement in higher order cognitive functioning. However, the P3 does not meet criteria for a pharmacodynamic or surrogate endpoint biomarker in this context, and the current evidence does not support EEG as a treatment-response biomarker for MPH in ADHD. Based on our findings, we make 10 recommendations for future research in this area."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Temporal Changes in Dispensing of Methylphenidate During Attention Deficit Hyperactivity Disorder Shortages in Australia: An Interrupted Time Series and Descriptive Analysis of National Dispensing Patterns. (PubMed, Pharmacoepidemiol Drug Saf) - "Methylphenidate dispensing in Australia became unstable during extensive supply shortages from late 2024. Although numerous S19A products were approved, there was minimal uptake of S19A PBS-listed products at the population level. As ADHD medicine utilisation continues to rise, strengthened national strategies to improve supply chain resilience, transparency and responsiveness are required."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Methylphenidate as a 'study drug': lessons from the COVID-19 infodemic for preventing non-medical use. (PubMed, Br J Psychiatry) - No abstract available

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Infectious Disease • Novel Coronavirus Disease • Psychiatry

Methylphenidate Versus Placebo for Treating Fatigue in Patients With Advanced Cancer: Randomized, Double-Blind, Multicenter, Placebo-Controlled Trial. (PubMed, J Clin Oncol) - "After 6 ± 2 weeks of treatment, methylphenidate was not superior to placebo for treating fatigue in advanced cancer. Methylphenidate was safe and well-tolerated."

Clinical • Journal • Metastases • Cardiovascular • CNS Disorders • Depression • Epilepsy • Fatigue • Hematological Disorders • Hypertension • Oncology • Palliative care • Psychiatry

Pharmacological and non-pharmacological modulation of striatal dopamine release: a meta-analysis of [11C]raclopride PET studies. (PubMed, Mol Psychiatry) - "To address this gap, in this meta-analysis of 92 [11C]raclopride PET studies (n = 1640), we compared the magnitude and regional distribution of dopamine release induced by amphetamine, methylphenidate, ketamine, alcohol, and cognitive challenges with and without reward. They also suggest that [¹¹C]raclopride PET may have limited sensitivity for distinguishing reward-related from non-reward-related dopamine release. These findings have implications for the design and interpretation of future neuroimaging studies of dopaminergic function in health and disease."

Journal • Retrospective data • Review

p.Gly143Glu Variant in CES1 Gene Associated with an Adverse Response to Methylphenidate in a Child: Case Report (PubMed, Acta Med Port) - No abstract available

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry • CES1

Pharmacotherapies for Co-Occurring Stimulant Use Disorder and Attention-Deficit/Hyperactivity Disorder: A Network Meta-Analysis. (PubMed, J Clin Psychiatry) - "Pharmacotherapies included methylphenidate (MPH), mixed amphetamine salt (MAS), and bupropion. Stimulant-based pharmacotherapies, particularly higher-dose MPH and MAS, were associated with superior outcomes for both stimulant-use indicators and ADHD symptoms. These findings support consideration of optimized stimulant dosing when treating co-occurring StUD and ADHD, though further trials are warranted to refine clinical recommendations."

Clinical • Journal • Retrospective data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

The Relationship between Physical Activity, Growth, Diagnosis, and Treatment in Children with Attention-Deficit/Hyperactivity Disorder (PubMed, Harefuah) - "Treatment with methylphenidate slightly mitigates the suppression of dopamine and growth hormone secretion in response to physical exertion, thereby providing at least a partial explanation for why stimulant medication in children with ADHD allows normal growth. The possible use of catecholamine and growth hormone responses to physical exertion for the diagnosis and treatment of children with ADHD requires further research."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Developmental Disorders • Psychiatry

Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy (clinicaltrials.gov) - P2 | N=175 | Active, not recruiting | Sponsor: M.D. Anderson Cancer Center | Trial completion date: Sep 2026 ➔ Sep 2028 | Trial primary completion date: Sep 2026 ➔ Sep 2028

Trial completion date • Trial primary completion date • Fatigue • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Lack of beneficial effect of planned treatment interruption in adults with ADHD treated with methylphenidate - clinical evidence. (PubMed, Psychiatry Res) - "In adult men receiving stable MPH treatment, planned weekend breaks were not associated with a clear overall advantage and were linked to less favorable diary-based behavioral functioning and more frequent selected self-reported cardiovascular adverse effects. Routine weekend discontinuation should not be assumed to improve treatment quality."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Cardiovascular • CNS Disorders • Cognitive Disorders • Psychiatry

Neurostimulants for disorders of consciousness in the intensive care unit: A systematic review. (PubMed, Gen Hosp Psychiatry) - "Neurostimulants were associated with short-term improvements in measures of arousal and recovery, although evidence remains heterogeneous and largely observational. Amantadine has the largest ICU evidence base; methylphenidate has been studied as monotherapy and augmentation; modafinil has primarily been evaluated for hypersomnolence. Further placebo-controlled trials are needed to establish efficacy across different causes of DoC; head-to-head studies are needed to clarify comparative effectiveness among available neurostimulants."

Journal • Review • Critical care

Examining Increased Ritalin and Adderall Use Among Low-Income People Who Use Drugs: Mixed Methods Study. (PubMed, JMIR Form Res) - "Crack and methamphetamine are also frequently used in combination with opioids to offset the sedating effects of adulterants such as fentanyl and xylazine in the unregulated drug supply. The use of prescription stimulants appears to be increasingly common among new populations of people who use opioids, including those who report very low incomes and even homelessness. Additional research is warranted to examine how this type of polysubstance use may require different types of prevention strategies."

Journal • Addiction (Opioid and Alcohol) • Anesthesia

Developmental deviations of association-network structural connectivity in youths with ADHD predict symptom and treatment outcomes. (PubMed, Nat Biomed Eng) - "Baseline deviations predicted 12-week treatment response to atomoxetine but not methylphenidate, and follow-up imaging revealed treatment-related reductions in deviation. Together, these findings identify structural connectivity deviation as a developmental biomarker with prognostic relevance for ADHD, supporting precision care through symptom monitoring and treatment stratification."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Time Trends in Maternal Attention-Deficit/Hyperactivity Disorder and Medication Use in Pregnancy. (PubMed, J Clin Psychiatry) - "Stimulant medication use (amphetamine, dextroamphetamine, lisdexamfetamine, methylphenidate) was assessed via prescription fills in the year before pregnancy, during pregnancy, and stratified by trimester. Approximately 75% of those prescribed a stimulant in the year prior to conception discontinued it prior to, or in, the first trimester of pregnancy, with stable time trends. The 4-fold increase in maternal ADHD in pregnancy over a 20-year period and 2-fold increase in the use of stimulant medication before and during pregnancy in this group underline the need for clinical guidance on managing ADHD in pregnancy."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Obstetrics • Psychiatry

Oral health status and associated influencing factors in children with attention-deficit/hyperactivity disorder: a case-control study. (PubMed, BMC Oral Health) - "Its core ADHD symptoms-inattention, hyperactivity, and impulsivity-impair oral hygiene behaviors, and first-line medications such as methylphenidate may further increase oral disease risk...These adverse oral health outcomes were associated with ineffective oral hygiene practices, frequent high-sugar dietary habits, ADHD-related neurobehavioral characteristics, and socioeconomic factors. Comprehensive oral health interventions integrating preventive clinical care, behavioral support, family involvement, and socioeconomic assistance are urgently needed for this population."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Dental Disorders • Inflammation • Mood Disorders • Pediatrics • Periodontitis • Psychiatry